Golchin-Rad Kamran, Mogheiseh Asghar, Nazifi Saeed, Ahrari Khafi Mohammad Saeed, Derakhshandeh Nooshin, Abbaszadeh-Hasiri Mohammad
Department of Clinical Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Fars, Iran.
Department of Clinical Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Fars, Iran.
Top Companion Anim Med. 2020 Mar;38:100405. doi: 10.1016/j.tcam.2020.100405. Epub 2020 Jan 23.
The monitoring of serum prostatic biomarkers during the treatment will help clinicians to know the statement of the response to finasteride in dogs affected by benign prostatic hyperplasia (BPH). The present study was aimed to assess changes in the serum canine prostate-specific esterase (CPSE), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), testosterone, dihydrotestosterone (DHT) and prostate volume evaluation using ultrasonographic examination during the treatment with finasteride in BPH-induced dogs. Twenty dogs were divided into 4 groups (n = 5): BPH + finasteride group, dogs which were induced for BPH and received oral finasteride once daily for 1 month; BPH group, dogs which were induced for BPH and received placebo; finasteride group, normal dogs which received finasteride; and normal group, normal intact dogs which did not receive treatment. Blood sampling and ultrasonography examination were performed on days 0, 14, and 28. The administration of finasteride led to a significant decrease in the concentration of the prostate-specific biomarkers (PSA, CPSE), DHT, testosterone, and the volume of the prostate in BPH + finasteride group compared with the BPH group during 1 month. Interestingly, the PAP concentration did not change in the BPH-induced dogs and in dogs treated with finasteride. It seems that the monitoring of serum PSA and CPSE levels and ultrasonographic examination of the prostate are useful methods for following up the response to finasteride treatment in dogs affected by BPH.
在治疗过程中监测血清前列腺生物标志物将有助于临床医生了解受良性前列腺增生（BPH）影响的犬只对非那雄胺的反应情况。本研究旨在评估在使用非那雄胺治疗BPH诱导犬的过程中，血清犬前列腺特异性酯酶（CPSE）、前列腺特异性抗原（PSA）、前列腺酸性磷酸酶（PAP）、睾酮、双氢睾酮（DHT）的变化以及通过超声检查评估前列腺体积。将20只犬分为4组（n = 5）：BPH + 非那雄胺组，诱导为BPH且每天口服非那雄胺1个月的犬；BPH组，诱导为BPH且接受安慰剂的犬；非那雄胺组，接受非那雄胺的正常犬；以及正常组，未接受治疗的正常未阉割犬。在第0、14和28天进行采血和超声检查。与BPH组相比，在1个月期间，非那雄胺的给药导致BPH + 非那雄胺组中前列腺特异性生物标志物（PSA、CPSE）、DHT、睾酮的浓度以及前列腺体积显著降低。有趣的是，在BPH诱导犬和接受非那雄胺治疗的犬中，PAP浓度没有变化。似乎监测血清PSA和CPSE水平以及对前列腺进行超声检查是跟踪受BPH影响的犬对非那雄胺治疗反应的有用方法。
